Humbert previously served as COO at France-based Limflow, a chronic limb-threatening ischemia (CLTI) treatment maker. She spent nearly seven years at Limflow, which designed its technology for transcatheter arterialization of deep veins. It diverts blood from a diseased tibial artery to a tibial vein to deliver oxygen to a patient’s ischemic foot.
However, in November 2023, Inari Medical closed a $415 million acquisition of Limflow. Months later, in May of this year, Humbert took to LinkedIn to share that she’d be assuming the corner office at Brightflow.
Humbert joins Brightflow with more than 20 years of experience in the medical device industry altogether. Before Limflow, she served as COO at Arterial Remodeling Technologies, a bioresorbable coronary stent maker. Her responsibilities at Brightflow include defining strategy, structuring the company, building out a team and adding value.
The Paris, France-based startup develops a long-term percutaneous, implantable system for supporting right ventricular (RV) failure without the need for open-heart surgery. Dr. Pascal Lim, the company’s president, said Humbert’s track record makes her the right person to lead Brightflow into its next phase of development. Lim said her appointment can strengthen the path forward to finalizing product development and commercializing the company’s implant.
“I was attracted to Brightflow’s smart concept for supporting right heart failure,” Humbert said in a news release. “By bringing this groundbreaking cardiovascular technology to market, I’m confident that we can change the lives of millions of patients for whom no real option exists today. The expertise of the R&D team and the quality of its leadership convinced me to join the Brightflow team.”
